PCI治疗对急性冠脉综合征患者血浆可溶性CD40配体及基质金属蛋白酶-9的影响  

Effects of PCI on Plasma Soluble CD40 Ligand and Matrix Metalloproteinase-9 in Patients with Acute Coronary Syndrome

作　　者：王蕊[1] 张鹏祥[1] 李飞星[1] 王晓元[1] 郝翠君 李会贤[1] 李方江[1] Wang Rui;Zhang Pengxiang;Li Feixing;Wang Xiaoyuan;Hao Cuijun;Li Huixian;Li Fangjiang(First Affiliated Hospital of Hebei North University,Zhangjiakou,075000)

机构地区：[1]河北北方学院附属第一医院

出　　处：《基因组学与应用生物学》2019年第10期4837-4841,共5页Genomics and Applied Biology

基　　金：张家口市科技攻关计划项目(1621077D)资助

摘　　要：为了分析经皮冠动脉介入治疗(percutaneous coronary intervention,PCI)对不同年龄组急性冠脉综合征(acute coronary syndrome,ACS)患者血清重组可溶性CD40配体(recombinant soluble CD40 ligand,sCD40L)和金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)水平的影响。本研究随机选取40例健康志愿者、就诊的40例急性心肌梗死(acute myocardial infarction,AMI)和40例不稳定心绞痛(unstable angina pectoris,UAP),按年龄≤60岁为一组,>60岁为一组,每组20例。分别在PCI治疗前1 d、治疗后1 d和7 d测定并统计各组间血清sCD40L和MMP-9水平变化。ACS患者血清sCD40L和MMP-9水平均明显高于对照组(p<0.05);>60岁的ACS患者血清sCD40L水平略高于≤60岁患者,但是无显著性差异(p>0.05);PCI治疗1 d后可增加ACS患者的血清sCD40L和MMP-9水平(p<0.01),7 d后则逐渐下降。ACS患者的血清sCD40L和MMP-9水平变化与年龄无明显关系;PCI治疗可能加重了冠状动脉内早期炎症,致使血清sCD40L和MMP-9水平在短期内增加,后期则逐渐恢复正常。To analyze the effects of percutaneous coronary intervention(PCI)on serum levels of recombinant soluble CD40 ligand(sCD40L)and metalloproteinase-9(MMP-9)in patients with acute coronary syndrome(ACS)of different ages.40 healthy volunteers,40 patients with acute myocardial infarction(AMI)and 40 patients with unstable angina pectoris(UAP)were randomly selected.According to age(<60 years old)as a group and(>60 years old)as a group.Serum levels of sCD40L and MMP-9 were measured before 1 day and after PCI 1 day,7 days respectively.The serum levels of sCD40L and MMP-9 in ACS patients were significantly higher than those in control group(p<0.05);The serum levels of sCD40L in ACS patients over 60 years old were slightly higher than those inACS patients under 60 years old,but therewas no significant difference(p>0.05);The serum levels of sCD40L and MMP-9 in ACS patients increased after 1 day of PCI treatment(p<0.01),but decreased gradually after 7 days.The changes of serum sCD40L and MMP-9 levels in ACS patients have no significant relationship with age;PCI treatment may aggravate the early inflammation of coronary artery,resulting in the increase of serum sCD40L and MMP-9 levels in a short period of time,and gradually return to normal in the later period.

关 键 词：急性冠脉综合征 经皮冠动脉介入治疗 重组人可溶性CD40配体 金属蛋白酶-9 

分 类 号：R54[医药卫生—心血管疾病]